Outcomes of patients registered with the Queensland Trophoblast Centre diagnosed with gestational trophoblastic neoplasia who develop resistance to chemotherapy
Australian and New Zealand Journal of Obstetrics and Gynaecology · 2025
DOI: 10.1111/ajo.13912 ↗Kurz gefasst
Fachartikel in der Zeitschrift Australian and New Zealand Journal of Obstetrics and Gynaecology, 2025. Verfasst von Meg Welsh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Metro North Hospital and Health Service, The University of Queensland Faculty of Medicine, Brisbane, Queensland, Australia. Hauptthemen laut MEDLINE: Gestational Trophoblastic Disease, Drug Resistance, Neoplasm, Antineoplastic Combined Chemotherapy Protocols, Uterine Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objectives
To audit outcomes of patients registered in the Queensland Trophoblast Centre (QTC) database who develop resistance to primary chemotherapy. To determine any risk factors that may predict first‐line chemotherapy resistance in patients diagnosed with gestational trophoblastic neoplasia (GTN).
Methods
Patients within the QTC who were diagnosed with GTN between January 2012 and December 2020 were reviewed.
Results
Of 138 patients with GTN registered in the QTC, 22 (15.9%) patients developed resistance to first‐line chemotherapy. Three had high‐risk GTN and 19 had low‐risk GTN. Of the three high‐risk patients, one patient died. This patient had an epithelioid trophoblastic tumour (ETT). The remaining two high‐risk patients had complete hydatidiform moles (CHM) with GTN. Both achieved complete remission with salvage therapy. Of the 19 low‐risk patients, one patient had a partial hydatidiform mole (PHM). This patient achieved remission following third‐line treatment. The other 18 low‐risk patients had CHM with GTN. All but two of these 18 patients were successfully treated with second‐line chemotherapy, with the remaining two patients achieving remission with third‐line chemotherapy. Five of the 18 patients received either actinomycin‐D or methotrexate as salvage therapy. Thirteen patients were given multi‐agent chemotherapy for second‐line treatment. One patient in this group died but this was not due to her disease. Initial β human chorionic gonadotropin levels were not predictive of number of chemotherapy cycles or number of lines of chemotherapy required to achieve remission.
Conclusions
GTN is a curable condition. If resistance to first‐line chemotherapy occurred, most patients achieved remission with salvage therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Metro North Hospital and Health Service, The University of Queensland Faculty of Medicine, Brisbane, Queensland, Australia.
- Obstetrics and Gynaecology Department, Redcliffe Hospital, Brisbane, Queensland, Australia.
- Queensland Trophoblast Centre, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
- Department of Gynaecologic Oncology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
ORCID-Profile: Meg Welsh
Zitieren
APA
Welsh, M., Morrison, S., Baartz, D., Sanday, K., & Garrett, A. (2025). Outcomes of patients registered with the Queensland Trophoblast Centre diagnosed with gestational trophoblastic neoplasia who develop resistance to chemotherapy. Australian and New Zealand Journal of Obstetrics and Gynaecology. https://doi.org/10.1111/ajo.13912
Vancouver
Welsh M, Morrison S, Baartz D, Sanday K, Garrett A. Outcomes of patients registered with the Queensland Trophoblast Centre diagnosed with gestational trophoblastic neoplasia who develop resistance to chemotherapy. Australian and New Zealand Journal of Obstetrics and Gynaecology. 2025. doi:10.1111/ajo.13912
BibTeX
@article{Welsh2025,
author = {Welsh, Meg and Morrison, Shona and Baartz, David and Sanday, Karen and Garrett, Andrea},
title = {Outcomes of patients registered with the Queensland Trophoblast Centre diagnosed with gestational trophoblastic neoplasia who develop resistance to chemotherapy},
journal = {Australian and New Zealand Journal of Obstetrics and Gynaecology},
year = {2025},
doi = {10.1111/ajo.13912}
}
EUVIMED